Overview

A Study to testABI-009 in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System

Status:
Terminated

Trial end date:
2021-02-26

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether ABI-009 will make advanced, malignant neuroendocrine tumor(s) of the lung, gastrointestinal tract and/or pancreas that cannot be removed by surgery smaller and slow the spread of your cancer in patients who have progressed or been intolerant to everolimus. All eligible participants will receive ABI-009, the study drug.

Phase:

Phase 2

Details

Lead Sponsor:

Robert Ramirez

Collaborator:

Aadi, LLC

Treatments:

Everolimus
Sirolimus